ICAT and its variations have become the gold standard for comparing global protein expression in many proteomics labs. But they may soon be rivaled by another strategy, recently published by Steven Gygi’s group at Harvard. Termed “Aqua” for absolute quantification, it promises to allow users to measure a small number of proteins — or their modification states — in large numbers of biological samples. Aqua assays are slated to be commercialized soon by Cell Signaling Technology, a company based in Beverly, Mass.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.